Whitehawk Therapeutics (WHWK) executive Dornan received 85,887 Stock Option (right to buy)

Insider transactions reported

David Dornan (Chief Scientific Officer at Whitehawk Therapeutics Inc., WHWK) reported that they received 85,887 Stock Option (right to buy) on Sep 15, 2026.

Reporting person

Dornan David

Role

Chief Scientific Officer

Options and other derivatives

Holdings before and after

• Stock Option (right to buy): 0 to 85,887 direct
• Restricted Stock Units: 0 to 85,887 direct

Footnotes from the filing

1. 1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
2. 2. Each restricted stock unit ( RSU ) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
3. 3. The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ